This is a good news that enrollment is completed. This is more important than previous milestones. With approx 2500 deaths per day, Lero is key drug to reach this stage (RDHL’s drug is just bit behind)
It can reduce hospitalization stay.
Show good results and it can EUA approval. It is show and win time.
I also like the trial design and clean primary and secondary end points. The primary end point is unambiguous and direct objective number.
The 14 day secondary end point is very good complimentary end point as it will tell other story.
Hopefully NP does not screw up this time in presenting the data. If successful, let them announce is effectively in a way that market understands.
——————-
. The primary outcome measured in this study is: all-cause mortality at Day 28.
Secondary outcomes measured are:
1) all-cause mortality at Day 14,
2) change in clinical status of subject at Day 14,
3) change in clinical status of subject at Day 28, and
4) change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.
News 
Market Data 
Discover 
AI
